poisar

Stocks · News reference

Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure

Vandana Singh

Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BMYMRKMRNAPSNLTEM
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight

    The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.

    ABBVLLYJNJNVSBMY
  2. Brendan Coffey

    Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

    The article compares Amgen and Novo Nordisk as investment options for 2026. Amgen shows stronger revenue growth (9.9%) with a diversified portfolio across oncology and rare diseases, while Novo Nordisk boasts higher profitability (33.1% net margin) but faces pricing pressures and competition in the GLP-1 market. The author recommends Amgen for 2026 due to its consistent revenue growth and scale advantages, despite Novo Nordisk's cheaper valuation multiples.

    AMGNNVOLLYBMYCELGR
  3. Eric Volkman

    Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters

    Bristol Myers Squibb announced positive Phase 3 trial results for izalontamab brengitecan (iza-bren), an experimental cancer drug that doubled progression-free survival time (11.1 months vs. 5.7 months) compared to chemotherapy in non-small cell lung cancer patients. However, the stock reaction was muted because the trial was conducted only in China, and FDA approval typically requires multi-region confirmatory data meeting Western standards. The drug represents part of BMY's strategy to transition from legacy medications to a growth portfolio.

    BMYCELGRJNJ